Positive Outlook for Plus Therapeutics: Strong Financial Support and Clinical Advancements Justify Buy Rating
Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Plus Therapeutics (PSTV – Research Report). The associated ...
INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights
New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an ...